Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL15058879 | 0.90 | HSP90AA1 (0.36) | CSNK2A1SMN1; SMN2TYMSPARP1ALDH1A1 | |
| SCHEMBL13606477 | 0.76 | CSNK2A2 (0.39) | CSNK2A1TYMSALDH1A1 | |
| SCHEMBL17702657 | 0.72 | CSNK2A1 (0.39) | CSNK2A1ADORA3SMN1; SMN2TYMSMAPT | |
| SCHEMBL9502126 | 0.72 | PARP1 (0.44) | CSNK2A1ADORA3SMN1; SMN2TYMSMAPT | |
| SCHEMBL15071204 | 0.72 | ADORA3 (0.32) | ADORA3 | |
| SCHEMBL5586200 | 0.69 | ADORA3 (0.50) | ADORA3SMN1; SMN2MAPTPARP1ALDH1A1 | |
| SCHEMBL30951806 | 0.69 | PARP1 (0.43) | PARP1 | |
| SCHEMBL16809188 | 0.69 | CSNK2A1 (0.37) | CSNK2A1ADORA3SMN1; SMN2TYMSMAPT | |
| SCHEMBL16809167 | 0.68 | CSNK2A1 (0.39) | CSNK2A1ADORA3SMN1; SMN2TYMSMAPT | |
| SCHEMBL22011133 | 0.68 | CSNK2A1 (0.39) | CSNK2A1ADORA3SMN1; SMN2TYMSMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815877-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815877-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013092940-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, PAK3 | CSNK2A1 470/4885ADORA3 2260/4885SMN1; SMN2 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.